AUS
NZ
UK
CA
USA
IND
.jpg)
Highlights
- COVID-19 cases have crossed the 1,000 mark across New Zealand.
- Summerset Group Holdings reveals the last day of sending director nominations.
- Green Cross Health is experiencing more-than-expected revenue and profitability due to a surge in the country’s COVID-19-related activity.
NZ health authorities reported a record 1,573 new community cases across the country today.
Auckland reported the maximum number of cases, amounting to 1,140, followed by Northland, Waikato, and Bay of Plenty, among other regions.
As of now, there are 8,147 active community cases across the nation.
To tackle the surge in COVID-19 cases, the NZ Government has outlined a three-staged plan, including testing changes and reduced isolation requirements.
That said, let us quickly take a look at the three NZX-listed healthcare stocks amidst increasing virus cases across the Kiwi nation.
Source: © 2022 Kalkine Media® data source- EODHD/Others
Fisher & Paykel Healthcare Corporation Limited (NZX:FPH; ASX:FPH)
In its H1 FY22 results, Fisher & Paykel Healthcare Corporation Limited recorded total operating revenue of NZ$900 million and an NPAT of NZ$222 million amid high demand for its products during the ongoing pandemic.
It had also distributed an interim dividend of 17.0 cps in December 2021, for the said period.
Owing to ongoing uncertainties, the Company expects its Hospital hardware sales will continue to be impacted by pandemic-related hospital admissions, hence, it has refrained from giving an earnings guidance for the remainder of FY22.
At the time of writing, on 17 February, FPH was declining by 0.14% at NZ$29.310.
Do Read: Fisher & Paykel (NZX:FPH): Which are its key markets and products?
Summerset Group Holdings Limited (NZX:SUM)
Summerset Group Holdings Limited Wednesday notified its shareholders that the last day of sending director’s nominations was 3 March.
Further, the retirement village operator will publish its FY21 financial results on 24 February.
Also Read: How are 3 NZX retirement villages faring amid Omicron outbreak?
At the time of writing, on 17 February, SUM was rising by 1.50% at NZ$11.500.
Green Cross Health Limited (NZX:GXH)
Green Cross Health Limited revealed that it was witnessing more-than-expected revenue and profitability due to increased COVID-19-related activity across its three divisions, namely medical, pharmacy and community health.
Related Read: 3 NZX penny stocks turning heads today despite a weak market
For the nine months ended 31 December 2021, the primary healthcare provider experienced a surge of 14% in its revenue on pcp.
Further, owing to an increase in Omicron cases, GXH anticipates a climb in its NPAT on the prior period by NZ$4.5 million-NZ$6.5 million, for the full-year ending 31 March 2022. The Group expects to release its FY22 results on 27 May 2022.
At the time of writing, on 17 February, GXH was dipping by 1.65% at NZ$1.190.
Bottom Line
The NZ Govt is leaving no stone unturned to safeguard its people from the infectious virus and to manage the spread of COVID-19 cases across the country.